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ABSTRACT
Identification of Molecules by Spectral Imaging
by Qamar A. Alshammari

Spectral imaging is a powerful technique which uses the wavelength to identify/quantify
the exact location and amount of the molecules. It facilitates the identification of materials
and studying their properties through analyzing the way they interact with light. The study
of light interaction with elements is called spectroscopy; spectroscopy examines how light
behaves in the target and recognizes materials based on their spectral signatures. Spectral
signatures can be compared to fingerprints which can be used to identify a person; spectral
signatures can be used to identify materials. Therefore, we hypothesize that identifying the
exact location and quantity of molecules present in the given cells samples can be done by
using a spectral imaging system. In this study, we identify the exact UV-Vis and
fluorescence spectra of organic substances including Rhodamine 6G, Doxorubicin and
UV-Vis spectra inorganic compounds including silver (Ag), gold (Au) nanoparticles (NPs).
After that, we used the Q-TOF LC/MS system to quantify the maximum and minimum
detectable concentrations of Rhodamine 6G and Doxorubicin by checking the chemicals
spectrum based on the molecular weight. In addition, we used HPLC system to quantify
the chemicals basing on their UV spectrum. Forwards, we used spectral imaging system to
determine the exact amount and location of the molecules within cells samples. For
Rhodamine 6G and doxorubicin, we started with the minimum detectable concentration by
Q- TOF and consider it as a maximum limit with spectral imaging. And for NPs we used
the maximum concentration for the analysis. Using the spectral imaging we were able to
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detect the exact location of Rhodamine 6G which was in the cytoplasm, Doxorubicin in
the nucleoplasm, and NPs in both. Furthermore, spectral imaging was able to detect much
lower concentrations of Rhodamine 6G and Doxorubicin by the spectrum in comparison
to Q-TOF LC/MS.
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Chapter 1
INTRODUCTION

1.1. General Introduction
Spectral imaging merges of two elements imaging and spectroscopy. The need to establish a threedimensional (3D) information which consists of various images of the same item, makes this
merging not meaningless. While other imaging systems can give the intensity at a broad
wavelengths, spectral imaging gives a spectrum at every pixel. This is a 3D informational
collection and can be seen as a cube shape of data (Fig 1). Combining the features of imaging and
spectroscopy is a superior way to understand the aspect of spectral imaging. Imaging is an
innovative science of getting spatial and temporal information from items for the reason of
collecting data. Right now, computerized imaging is the most developed and appropriate strategy
where data are recorded utilizing an advanced camera, for example, a charged coupled device
(CCD). In biologic examinations, the images can be estimated either by basic optical strategies,
for example, optical microscopy or by further developed techniques like time-lapse imaging. The
quality of an image decides the measure of information that can be extracted from it. The most
basic parameters that describe the gained images: spatial resolution 250 nm (in-plane) at λ 500 nm,
most reduced signal relies upon the quantum productivity of the detector (the higher the better).
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Figure 1 Demonstrating of a spectral image data, each point in the cube clarify a single number.
Because spectral image is explained as I(x,y,l), it can be observed as spectrum I(l) at every pixel
I(x,y) or as an image I(x,y) at each wavelength I(l)
1.2. Spectroscopy
Spectroscopy, the study of securing and clarifying the spectral qualities of an object, is a science
that has been generally studied for centuries. A spectrum is a collection of light intensities at
various wavelengths. The structure of particles and atoms is specifically identified with
spectroscopy. The spectrum is an immediate estimation of the energy levels of the defined
structure. To quantify a spectrum, the light is scattered into its different wavelength (or color)
elements, and the intensity at every wavelength is estimated. Most valuable features of a spectrum
include spectral resolution 1–20 nm (may depend on λ) within spectral range of 400–900 nm.
Spectral imaging approaches can be separated into the following techniques: (1) Wavelength-scan
approaches that measure the pictures at one wavelength at any given moment. (2) Spatial-scan
techniques that measure the entire spectrum of a part of the image at a time and scan the picture
(e.g., line by line). (3) Time-scan methods that measure a set of images where every single one of
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them is a superposition of spectral or spatial picture data. Toward the finish of the capturing, the
information is converted to the real spectral image (e.g., by Fourier strategies) image (e.g., by
Fourier strategies). (4) Approaches that measures the entire spectral picture at the same time, but
accord on the number of points in the spectrum, the spatial resolution (Garini et al., 2006).

1.3. Spectral Imaging Types
Spectral imaging can be separated into multispectral imaging, hyperspectral imaging (HSI), and
ultra-spectral imaging. Multispectral imaging system gathers information in few and generally
noncontiguous wide spectral bands, estimated in micrometers or tens of micrometers, whereas HSI
can collect hundreds of spectral bands. Ultra-spectral imaging system gathers considerably more
data. One of the significant benefits of spectral imaging technique is that it can obtain reflectance,
retention, or fluorescence spectrum for every pixel in the image, which can be utilized to
distinguish the biochemical alteration of items that cannot be analyzed by conventional gray or
color imaging techniques. As indicated by the electromagnetic hypothesis, diverse biochemical
constituents regularly have distinctive spectral signatures or marks. These marks generally created
by the associations amongst materials and electromagnetic waves, for example molecule vibration.
(Li et al., 2013).

1.4. Spectral Imaging Applications
The biological and pathological differences in tissues and organs have a close connection with the
spectra. Spectral aspects in various wavelength areas yield a detectable spectral signature, making
pathological alteration observable. Along these lines, the spectral imaging method additionally can
be reached out to the biomedical engineering field to evaluate the physiological status of living

3

tissues, since it can exploit the spatial connections among the diverse spectra in a neighborhood.
This innovation opens new prospects for science by which researchers can recognize and evaluate
the connections among biologically active molecules, analyze living life forms noninvasively,
carry out histopathological and fluorescent analyses, and improve natural explaining of illnesses.
This character makes it conceivable not exclusively to distinguish some physiological changes of
organic tissues by their spectral marks, yet additionally for early conclusion of a few ailments since
the states of the spectra yield data about natural samples (Li et al., 2013). To date, tissue
fluorescence was an outstanding amongst other techniques for improving the customary
endoscopic determination of gastrointestinal (GI) sores. Tissues are lighted with ultraviolet (UV)
or short wavelength visible (VIS) light from a laser or separated light source. This kind of tissue
fluorescence that can be seen in the tissues is called "autofluorescence." The chemical groups in
charge of the autofluorescence are called "fluorophores". Each group of fluorophores is identified
by unmistakable excitation and emission wavelength ranges. It is normal for a single excitation
wavelength to energize numerous fluorophores. Tissues additionally contain chemical groups
called "chromophores" that retain light without re-discharge of fluorescence. The retention is
firmly wavelength dependent and may fundamentally adjust the in vivo fluorescence range visible
at the tissue surface. The fundamental chromophore in the live tissues in the obvious wavelength
(400–700 nm) is hemoglobin. While each fluorophore has a particular fluorescence spectrum,
tissues have a blend of many fluorophores that appear at in various concentration and at various
depth. Changes in the characteristic fluorescence of the tissue layers with illness are because of
modifications in their biochemical organization (metabolic state, microenvironment).
Furthermore, alterations in the layer thicknesses or the blood components lead to the fluorescence
contrasts seen amongst normal and unhealthy tissues. These fluorescence contrasts might be
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adequate to recognize ordinary and infected tissues. In this manner, one of the application example
is the utilization of autofluorescence for identification of early malignancies or premalignant
colonic sores is subject to a changes in at least one of the accompanying components: (a) the tissue
construction (mucosal thickening); (b) the light retention and scattering aspect at every layer, (c)
the dispersion and concentration of fluorophores in the distinctive layers; (d) the biochemical
microenvironment of the tissue, that may modify the fluorescence output or spectral form
(DaCosta et al., 2007).
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Chapter 2
METHODOLOGY

2.1. Materials
The chemicals in this project include: anhydrous methanol HPLC grade (99.8%) and acetonitrile
HPLC grade (≥ 99.9%) were purchased from SIGMA-ALDRICH, Rhodamine 6G (MW: 479.01
g/mol) from SIGMA. Doxorubicin (MW: 579.98 g/mol) was obtained from TCI AMERICA.
Trifluoroacetic Acid (TFA) from EMD Millipore Corporation, Formic Acid, and sucrose from
Fisher Scientific (Fair Lawn, NJ). LL-CPK1 (ATCC® CL101.1TM) porcine renal epithelial cells
from proximal tubule were obtained from American Type Culture Collection (ATCC; Manassas,
VA). Trypsin, penicillin-streptomycin solution, Phosphate Buffered Saline (PBS) and Dulbecco's
Modified Eagle Medium (DMEM) were purchased from Corning (Manassas, VA). Fetal bovine
serum (FBS) was obtained from Seradigm (Logan, UT). Paraformaldehyde (PFA) from Electron
Microscopy Services (Hatfield, PA) and Mounting Media HistoChoiceÒ from AMRESCO.

2.2. Cell culture
LL-CPK1 cells were cultured to a confluent monolayer in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at
37°C in 5% CO2 and 95% humidity. Cells were trypsinized (using a 0.05% solution of trypsin)
regularly for passage when reached 70-90% confluence. For this research, cells were cultured to
reach 70-80% confluence before treated with the chemicals.
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2.3. UV-VIS and Fluorescence Spectrum Detection
SpectraMax M5 Spectrophotometer was used to read the UV visible spectrum for doxorubicin,
rhodamine 6G, silver (Ag) and gold (Au) nanoparticles (NPs). In addition, it was used to read the
fluorescence spectrum for doxorubicin and Rhodamine. Table 1 describes the concentrations of
the chemicals used in this method. Doxorubicin and Rhodamine were prepared at the same
concentrations in methanol. Whereas Ag and Au NPs were diluted in Milli-Q water at different
concentrations. The wavelength range of 200 – 800 nm was used to read UV spectrum for all
chemicals. The fluorescence spectrum range was 400 - 800 nm for Doxorubicin and Rhodamine.

Table 1. Different concentrations of the chemicals were prepared to read the UV-VIS and
fluorescence spectrums by spectrophotometer. Methanol was used to prepare the stock solutions
of Doxorubicin and Rhodamine 6G at concentrations of 0.2 mM and 0.3 mM respectively. While
Ag and Au NPs were diluted with Milli-Q water at different concentrations.

Spectrum
Detection

Doxorubicin

Rhodamine 6G

Ag NPs

Au NPs

UV-VIS

1, 0.75, 0.5, 0.25,
0.1 µM

1, 0.75, 0.5,
0.25, 0.1 µM

100, 37.5, 25,
12.5, 5 mg/mL

100, 37.5, 25, 12.5,
5 mg/ml

Fluorescence

1, 0.75, 0.5, 0.25,
0.1 µM

1, 0.75, 0.5,
0.25, 0.1 µM

---

---
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2.3. Detection and Quantification of Mass Spectrometry and UV Detection Limits
Quadruple Time of Flight Liquid Chromatography / Mass Spectrometry (Q-TOF LC/MS) (Bruker
Impact II™ and Ultimate 3000 UPLC (Dionex) was used to detect and quantify the maximum and
lower detection limits based on the mass spectra for both Doxorubicin and Rhodamine 6G. MS
method was performed by direct injection of different concentrations of Doxorubicin and
Rhodamine (Table 2), between every single injection, methanol HPLC grade was used to wash the
LC tubing. For Q-TOF LC/MS method, Doxorubicin was prepared at different concentrations
(Table 2) and eluted by using gradient of solvent (A) 0.1% formic acid in Milli-Q water and (B)
0.1% formic acid in acetonitrile. The flow rate was 0.3 mL/min, and the injection volume was 50
µL with a total acquisition time of 10 min. The reversed phase-high liquid chromatography (RPHPLC) C18 column (Shimadzu 50 ´ 4.6mm, 3µm particle size) was used in the analysis. (Table
3) In addition, Rhodamine was also prepared at different concentrations (Table 2) and analyzed by
using the isocratic elution method in 100% methanol and an injection volume of 50 µL (Fig 2).
However, to quantify the limits of Doxorubicin and Rhodamine in the UV spectrum wavelength,
analytical Hitachi HPLC was use. The gradient elution was conducted using mobile phase (A)
0.1% trifluoroacetic acid in Milli-Q water and (B) 0.1% trifluoroacetic acid in acetonitrile with the
same gradients of Q- TOF method for Doxorubicin as shown in Table 3. Rhodamine was also
analyzed with the isocratic method that has been used in Q- TOF.
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Table 2. Rhodamine 6G and doxorubicin detectable concentrations for quantifying the mass
and UV spectra by Q- TOF and HPLC.
Method

Rhodamine 6G

Doxorubicin

Q-TOF MS

5.0, 3.0, 2.5, 2.0, 1.5, 1.0,
0.5, 0.3, 0.2 nM.

5.0, 3.0, 1.5, 1µM, 500, 450,
300, 150 nM.

Q- TOF LC/MS

5.0, 3.0, 2.5, 2.0, 1.5, 1.0,
0.5, 0.3, 0.2 nM.

5.0, 3.0, 1.0µM, 500, 300, 150
nM.

5.0, 3.0, 2.5, 2.0, 1.5, 1.0,
0.5, 0.3, 0.2 nM.

5.0, 3.0, 1.0µM, 500, 300, 150
nM.

HPLC-UV

Table 3. RP-HPLC gradient for the separation of doxorubicin.
Time (min)

%A

%B

Flow Rate (mL/min)

0

95

5

0.3

0

95

5

0.3

1.5

95

5

0.3

6

5

95

0.3

7

5

95

0.3

7.1

95

5

0.3

9

95

5

0.3

9

Figure 2. The sequence of steps for Q-TOF LC/MS.
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2.4. Cell Treatment
Cells were seeded into sterilized 22x22 mm coverslip (globe Scientific Inc), in 6 well plate
(Greiner bio-one CELLSTARâ, total volume of 2 mL at each well) under normal growth
conditions until reached 70–80% confluency. The cells then were treated with 100 µL of the
selected chemical at different concentrations ranging from 150 to 1 nM for Doxorubicin, 100 µM
to 0.01 nM for Rhodamine 6G and 100 mg/mL for NPs (Table 4). The cells were treated for a total
incubation time of 18 hrs. Then, cells were fixed for 10 min in fixing solution (2.5 mL PFA, 7.5
mL PBS and 0.2 g sucrose) at room temperature; afterward, cells were washed 3 times with PBS
5 min each time. After that, the coverslip was placed on the slide that contains 25 µL of Mounting
Media overnight at room temperature (Fig 3).

Figure 3. The sequence of steps for the cells treatments and analysis for spectral imaging.
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Table 4. Selected chemical concentrations for spectral imaging

Spectral Imaging

Concentrations

Doxorubicin

Rhodamine 6G

NPs

150, 100, 10, 1 nM

100 µM, 0.2, 0.08,
0.01 nM

100mg/mL

2.5. Spectral Imaging
Spectral imaging instrument (ASI Spectral Imaging System, OLYMPUS) was used in this research.

Manual image acquisition was conducted with 60× magnification fields. For spectral imaging data,
the pure doxorubicin, rhodamine 6G, Ag and Au NPs spectral wavelengths were identified at the
beginning. Then, we uploaded these spectrums as libraries for further cells analysis. Subsequently,
images of the cells that treated with chemicals were captured randomly by using SKY and
brightfield filters at least 10 capturing at each concentration. Afterward, we analyzed the captured
image by using spectrum libraries of the chemicals and scanned all the interesting area to obtain
the location that matched with spectrum wavelength library (Fig 4).
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Figure 4. The sequence of steps for the spectral imaging data acquisition.

2.6. Statistical Analysis
Most of our statistical analysis was conducted by using Spectral Imaging software version
7.2.7.34276 and GraphPad Prism software version 8.0. Microsoft Excel software version 16 was
also used for linear regression analysis to obtain a standard calibration curve and linear equation.
Comparisons between two groups were analyzed with two-tailed student-t tests. Comparisons of
three or more groups were done using ANOVA analysis followed by a posthoc test. BioRender
software was also used to draw the figures in this research.
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Chapter 3
RESULTS AND DISCUSSION

3.1. Spectrophotometer
The UV Spectra of Rhodamine 6G with concentration range 1 – 0.1 µM show excitation at ~ 530
nm, which was compared with previous studies and showed consistent results (Fig 5b). Using the
scanning spectrophotometer we obtained a wavelength of fluorescence emission spectrum at ~580
nm, which is also consistent with previous researches (Chapman et al., 2016) (Fig 5a). We further
conducted a linear regression analysis to evaluate the validity and the linearity of the concentrationdependent data. The relationships displayed in the scatterplots in Fig 6a and b of the coefficient of
determination (R2) of rhodamine 6G is linear between intensities at different concentrations and
the wavelengths, at R2= 0.99 and 0.95 for excitation and emission spectrum respectively.
Doxorubicin excitation wavelength was found at ~483 nm for concentrations range 1 – 0.1 µM,
which is consistent with previous studies (Liang et al., 2018) (Fig 7a). At the same concentrations,
fluorescence emission wavelength was found ~592 nm (Fig 7b). In addition, linear regression
analysis was conducted for excitation and emission spectrum data points. In the scatterplots in Fig
8a and b, the data point relationships showed linearity between intensities and the wavelengths at
different concentrations of excitation and emission spectrum, at R2= 0.96 and 0.89 respectively.
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Figure 5. (a) Fluorescence emission wavelength of Rhodamine 6G with methanol at ~ 580 nm with each
concentration. (b) Spectrophotometer excitation wavelength of Rhodamine 6G with methanol at ~ 530
nm with each concentration. The lower graphs of a and b are the enlarged scale of the area interested.
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a.
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R² = 0.9577

400
200
0
0.00

0.25

0.50

0.75

1.00

1.25

Concentration (µM)
Figure 6. (a) Linear regression analysis of Rhodamine 6G excitation wavelength.
X= concentrations range from 1 – 0.1 µM, y= average intensity. (b) Linear
regression analysis of Rhodamine 6G emission wavelength (580 nm). X=
concentrations range from 1 – 0.1 µM, y= average of intensity.
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Figure 7. (a) Spectrophotometer excitation wavelength of Doxorubicin with methanol at ~483 nm with
each concentration. (b) Spectrophotometer emission wavelength of Doxorubicin with methanol at ~592
nm with each concentration. The lower graphs of a and b are the enlarged scale of the area interested.
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Figure 8. (a) Linear regression analysis of Doxorubicin excitation wavelength. X= concentrations
range from 1 – 0.1 µM, y= average of intensities. (b) Linear regression analysis of Doxorubicin
emission wavelength. X= concentrations range from 1 – 0.1 µM, y= average of intensities.
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Further, Ag and Au NPs were scanned via spectrophotometer in 200 – 400 nm. AuNPs excitation
wavelength was found at ~536 nm which is consistent with the expectation of previous researchers
(between 520 and 580 nm, Haiss, Thanh, Aveyard, & Fernig, 2007) (Fig 9a). As well as Ag NPs
excitation wavelength at ~ 420 nm that is also consistent with previous studies (Fayaz et al., 2010)
(Fig 9b). In addition, linear regression analysis was perfumed for NPs. As shown in Fig 10a and
b the scatterplots of NPs, there is a linear relationship between intensities and the wavelength at
different concentrations of Au and AgNPs at R2= 0.94, 0.97 respectively.
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Figure 9. (a) Spectrophotometer excitation wavelength of gold NPs with Milli-Q water at ~ 536 nm
with each concentration. (b) Spectrophotometer excitation wavelength of silver NPs with Milli-Q water
at ~ 420 nm with each concentration. The lower graphs of a and b are the enlarged scale of the area
interested.
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3.2. Q- TOF MS and LC/MS
To quantify the maximum and minimum mass spectrometry concentrations limits of the selected
chemicals, Q-TOF MS and LC/MS was conducted. For Q-TOF MS method, Rhodamine was by
injected at different concentrations (Table 2) and by checking the molecular mass the maximum
concentration limit to detect at 5 nM (Fig 11), while 0.2 nM is the minimum concentration with
precursor ion at m/z 443 Da which consistent with previous studies (Ferreira et al., 2017) (Fig 12).
Linear regression analysis was performed to check the validity of our MS data point. The
scatterplot in Fig 13 showed the relationship between intensities and different concentrations at
m/z 443 Da of MS data. There is linear relationship result between the MS data particularly from
0.2 to 2 nM at R2= 0.9, from 2.5 to 5 nM the line becomes flat which it might be considering a
sign of saturation. Furthermore, Q- TOF LC/MS was performed for Rhodamine at the same
concentrations as Q-TOF MS method. The detection of LC/MS data was done by using 3 µm
column via checking the molecular mass of the chemical at each concentration. The maximum and
minimum concentrations of detectable limits of Rhodamine concentration were consistent with
MS data, at 5 – 0.2 nM respectively (Fig 14, 15). The linear analysis also conducted on Q- TOF
LC/MS data, and it showed a good linearity relationship between the area under the curve (AUC)
of the intensities vs. concentrations, R2= 0.98 (Fig 16). For a better comparison between spectral
imaging and LC/MS data, UV quantification of Rhodamine 6G was also performed by using
analytical HPLC. The limits concentrations detectable for rhodamine 6G UV peaks (at 530 nm)
were consistent with Q- TOF MS and LC/MS data which at 5 – 0.2 nM (Fig 17, 18). The linearity
of AUC for UV peaks and intensities shown in Fig 19, our data point showed a good linearity (R2=
0.98) but because we set all the data at zero, it gave a lower linear relationship (R2= 0.66) in
comparing with Q- TOF MS and LC/MS data.
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Figure 11. Q- TOF MS result for direct injection of Rhodamine 6G at the concentration of 5 nM
(which is considered to be the maximum concentration limit), precursor ion at m/z 443 Da.
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Figure 12. Q- TOF MS result for direct injection of Rhodamine 6G at the concentration of 0.2 nM
(which is considered to be the minimum concentration limit), precursor ion at m/z 443 Da.
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Figure 13. Linear regression analysis of Rhodamine Q-TOF MS data. X=
concentrations range from 5 – 0.2 nM, y= average of intensities of m/z 443 Da.
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Figure 14. Q- TOF LC/MS result for the AUC of Rhodamine 6G at the concentration of 5 nM
(which is considered to be the maximum concentration limit), precursor ion at m/z 443 Da.
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Figure 15. Q- TOF LC/MS result for the AUC of Rhodamine 6G at the concentration of 0.2 nM
(which is considered to be the minimum concentration limit), precursor ion at m/z 443 Da.
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Figure 16. Linear regression analysis of Rhodamine Q-TOF LC/MS AUC
data. X= concentrations range from 5 – 0.2 nM, y= average of intensities of
m/z 443 Da.

27

Figure 17. Analytical HPLC chromatograph result for the AUC of Rhodamine 6G at the concentration of
5 nM (which is considered to be the maximum concentration limit), the UV detection at 530 nm.
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Figure 18. Analytical HPLC chromatograph result for the AUC of Rhodamine 6G at the concentration of
0.2 nM (which is considered to be the minimum concentration limit), the UV detection at 530 nm.
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Figure 19. Linear regression analysis of rhodamine HPLC - UV AUC data. X=
concentrations range from 5 – 0.2 nM, y= average of intensities of 530 nm.
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Doxorubicin Q- TOF MS and LC/MS were also conducted to quantify the maximum and minimum
mass spectrometry concentrations detectable limits and further compare it with the spectral
imaging system. Doxorubicin was directly injected at different concentrations (Table 2) for QTOF MS analysis. By checking the molecular mass the maximum concentration limit to detect was
determined at 5 µM (Fig 20), while the minimum detection limit is 150 nM (Fig 21). The precursor
ion was found at m/z 544 Da which is consistent with previous researches (Sottani, Poggi,
Melchiorre, Montagna, & Minoia, 2013). Linear regression analysis was done to check the validity
of the Q-TOF MS data. The relationship between different concentrations at m/z 544 Da and the
intensities of MS data is showing in the scatterplot in Fig 22. Linear relationship results between
the MS data especially from 150 nM to 1 µM at R2= 0.86, from 1.5 to 5 µM the line starts to
become flat which could be considered a sign of saturation. Also, at the same concentrations of
Q- TOF MS method, doxorubicin was prepared to perform Q- TOF LC/MS analysis. The detection
of the data was conducted by using a 3 µm column through testing the molecular mass of the
chemical at each concentration. The maximum and minimum concentrations detectable limits were
consistent with MS data, at 5 µM – 150 nM respectively (Fig 23, 24). Linear consideration was
conducted on Q- TOF LC/MS, it showed an excellent linearity relationship between the intensities
and AUC of the concentrations, R2= 0.99 (Fig 25). At the same way of Rhodamine, analytical
HPLC analysis was performed for UV quantification of Doxorubicin in order to compare spectral
imaging and LC/MS data. Doxorubicin UV peaks for the detectable concentrations limits (at 483
nm) were consistent with Q- TOF MS and LC/MS data which at 5 µM – 150 nM (Fig 26, 27). The
linearity of the intensities and AUC- UV peaks are shown in the scatter plot, the result here also
represent an excellent linear relationship between our data point (R2= 0.99) (Fig 28).
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Figure 20. Q- TOF MS result for direct injection of Doxorubicin at the concentration of 5µM (which is
considered to be the maximum concentration limit), precursor ion at m/z 544 Da.
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Figure 21. Q- TOF MS result for direct injection of Doxorubicin at the concentration of 150 nM
(which is considered to be the minimum concentration limit), precursor ion at m/z 544 Da.
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Figure 22. Q- TOF MS Linear regression analysis of Doxorubicin data. X=
concentrations range from 5 µM – 150 nM, y= average of intensities of m/z 544
Da.
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Figure 23. Q- TOF LC/MS result for the AUC of Doxorubicin at the concentration of 5 µM (which is
considered to be the maximum concentration limit), precursor ion at m/z 544 Da.
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Figure 24. Q- TOF LC/MS result for the AUC of Doxorubicin at the concentration of 150 nM (which is
considered to be the minimum concentration limit), precursor ion at m/z 544 Da.
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Figure 25. Q- TOF LC/MS AUC linear regression analysis of Doxorubicin data. X=
concentrations range from 5 µM – 150 nM, y= average of intensities of m/z 544 Da.
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Figure 26. Analytical HPLC chromatograph result for the AUC of doxorubicin at the concentration of 5µM
(which is considered to be the maximum concentration limit), the UV detection at 483 nm.
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Figure 27. Analytical HPLC chromatograph result for the AUC of doxorubicin at the concentration of 150
nM (which is considered to be the minimum concentration limit), the UV detection at 483 nm.
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Figure 28. Linear regression analysis of doxorubicin HPLC - UV AUC data. X= concentrations range
from 5 µM – 150 nM, y= average of intensities of 483 nm.
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3.3 Spectral Imaging
3.3.1 Rhodamine Spectral Imaging result
The spectral imaging measurements were conducted by using SKY filter for pure rhodamine 6G
fluorescence wavelength at ~ 580 nm which was detected using spectrophotometer. However, pure
Rhodamine (dye alone) with spectral imaging system gives an additional wavelength peak at ~
670 nm which we didn’t identified yet (Fig 29b). These wavelengths were uploaded and saved as
libraries for further treated cell analysis.
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Figure 29. (a) Pure Rhodamine 6G brightfield image by using brightfield filter, spectral image by using
SKY filter which represents the uploaded Rhodamine library analysis and merged image which is merged
between brightfield and spectral images. (b) The graph represents pure Rhodamine 6G fluorescence
wavelength at ~ 580 nm, 670 nm, X= wavelengths (580, 670 nm) and Y= signal intensity. Inside represents
the area that contains brighter fluorescence dye and higher intensity in comparing with the peripheral zone,
while background showed the wavelength of the background area of rhodamine. (c) The bars showed the
intensity variation of the data point for peak1 which is higher than peak2.
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Fig 29a showed the brightfield image of pure Rhodamine obtained by using brightfield filter, a
spectral image which was done by using SKY filter. Its represent the uploaded wavelength library
analysis, and merged image that merged between brightfield and spectral images. The graph in Fig
29b represents different fluorescence wavelengths of pure rhodamine 6G at ~ 580 nm, 670 nm.
The inside showed the area that has brighter fluorescence dye and higher wavelength intensity in
comparison to the peripheral area, background showed the wavelength intensity of the chemical
background. In addition, the bars (Fig 29c) illustrate the intensity data point variation of peak1
which is higher than peak2. Furthermore, analysis of the cell that treated with rhodamine 6G was
also conducted in this research. Cells were treated at different concentrations starting with 0.2 nM
as the minimum concentration detectable by Q- TOF (Table 4) for 18 hrs and then the cells were
fixed for spectral imaging analysis. Fig 30a represented the brightfield, spectral and merged images
of the negative control which is untreated cells. Fig 30b showed the difference between cytoplasm
and nucleoplasm wavelength which are considered to be background in compare with the positive
control (pure dye). In order to show the saturation area inside the cells, 100 µM of Rhodamine 6G
was used to treat the cells for 18 hrs. Fig 31a showed the brightfield image, a spectral image (by
using SKY filter) which is the result of the uploaded libraries of pure Rhodamine and merged
images of the cells that treated with 100 µM of the dye. The spectral image also showed the
rhodamine location in the cell which is specified in the cytoplasm. Fig 31b illustrates different
fluorescence wavelengths of 100 µM treated cells at ~ 580 nm, 670 nm, which are consistent with
pure dye results. However, there is an additional small peak at ~ 530 nm which we didn’t identify
it yet. Blue wavelength represented the cytoplasm rhodamine spectrum, and red wavelength
showed the spectrum of rhodamine in the cell nucleoplasm. The bars (Fig 31c) illustrate the
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intensity data point diversity of peak1 which is higher than peak2, and this diversity was consistent
with peaks variations of the pure rhodamine.
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Figure 30. (a) Negative control of the untreated cells brightfield image by using brightfield filter,
spectral image by using SKY filter and merged image which is merged between brightfield and spectral
images. (b) The graph represents negative control fluorescence wavelengths which are considered to
be a background in comparing with the positive control, X= wavelengths and Y= signal intensity. (c)
The bars showed the intensity variation of the data point for untreated cells.
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Figure 31. (a) Brightfield image of treated cells with 100 µM of Rhodamine 6G image by using
brightfield filter, spectral image by using SKY filter which represented the result of uploaded
Rhodamine library and the saturation area is showing in the lower left part of the image. The
spectral image also showed the rhodamine location in the cell which is specified in the cytoplasm.
The merged image which is a combination of brightfield and spectral images. (b) The graph
represented Rhodamine 6G fluorescence wavelength at ~ 580 nm, 670 nm inside the cells, X=
wavelengths and Y= signal intensity. The blue wavelength shows the area that contains Rhodamine
fluorescence which is in the cytoplasm, while the red wavelength represents the spectrum of the
area in the cell nucleoplasm. (c) The bars showed the intensity variation of the data point for peak1
which is higher than peak2, and this variation in consistent with pure dye data pint results.
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Forward, we treated the cells with 0.2 nM of rhodamine which is considered to be the maximum
limit to detect this dye in comparison with Q- TOF. Fig 32a demonstrated the brightfield image,
spectral image which is the result of the uploaded libraries of pure Rhodamine and merged images
of the cells that treated with 0.2 nM of the dye. Fig 32b showed different fluorescence wavelengths
of 0.2 nM treated cells at ~ 580 nm, 670 nm, which are consistent with pure and 100 µM dye
results. The blue wavelength represents the cytoplasm spectrum of Rhodamine and red wavelength
showed the spectrum of the cell nucleoplasm. The bars in Fig 32c explained the variety of intensity
data point of peak1 which is higher than peak2, and this variation consistent with peaks variations
of the pure and 100 µM rhodamine results. In addition, the intensities at this concentration become
lower than pure and 100 µM Rhodamine samples which are expected since we prepare lower
concentrations. Since rhodamine can be detectable at a concentration of 0.2 nM, we treated cells
with much lower concentration at 0.08 nM. Fig 33a showed the brightfield image by brightfield
filter, spectral image which is the result analysis of the uploaded libraries of pure Rhodamine (the
system also showed rhodamine location in the cell which is in the cell cytoplasm) and merged
images of the cells that were treated with 0.08 nM of the dye. Fig 33b demonstrated different
fluorescence wavelengths of 0.08 nM treated cells at ~ 580 nm, 670 nm, which are consistent with
pure, 100 µM and 0.2 nM dye results. Blue wavelength clarifies the cytoplasm spectrum of
Rhodamine and red wavelength showed the spectrum of the nucleoplasm of the sample. The bars
in Fig 33c interpreted the data point intensity variation of peak1 which is higher than peak2, this
variation consistent with peaks variations of the pure, 100 µM and 0.2 nM Rhodamine results.
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Figure 32. (a) Cells treated with 0.2 µM of Rhodamine 6G brightfield image by using brightfield
filter, spectral image by using SKY filter which represented the result of uploaded rhodamine
library and merged image which is a combination of brightfield and spectral images. (b) The graph
represented Rhodamine 6G fluorescence wavelength at ~ 580 nm, 670 nm inside the cells, X=
wavelengths and Y= signal intensity. The blue wavelength explained the area that contains
Rhodamine fluorescence which is in the cytoplasm, while red wavelength showed the spectrum
of the area which was in cell nucleoplasm. (c) The bars showed the intensity variation of the data
point for peak1 which is higher than peak2, and this variation in consistent with pure dye data pint
results. The intensities here become lower in comparing with pure and 100 µM rhodamine since
we prepared lower concentration.
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Figure 33. (a) Brightfield image of the cells that treated with 0.08 µM of Rhodamine 6G by using
brightfield filter, spectral image by using SKY filter which represented the result of uploaded
Rhodamine library and merged image which is a combination of brightfield and spectral images.
(b) The graph represented Rhodamine 6G fluorescence wavelength at ~ 580 nm, 670 nm inside
the cells, X= wavelengths and Y= signal intensity. The blue wavelength showed the area that
contains Rhodamine fluorescence which is in the cytoplasm, while red wavelength explained the
spectrum of the cell nucleoplasm. (c) The bars illustrated the data point intensity variation of
peak1 which is higher than peak2, this variation consistent with peaks variations of the pure, 100
µM and 0.2 nM rhodamine results. The intensities here become lower in comparing with pure and
100 µM rhodamine since we prepare lower concentration.
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Then, we treated cells with 0.01 nM of rhodamine for further analysis. Fig 34a interpreted the
brightfield image which has been done by brightfield filter, a spectral image which is considered
to be the result analysis of the uploaded libraries of pure Rhodamine. The spectral image also
illustrates the dye location in the cell which is in the cytoplasm. The merged image is a combination
of spectral and brightfield images of 0.01 nM Rhodamine. Fig 34b showed different fluorescence
wavelengths of 0.01 nM treated cells at ~ 580 nm, 670 nm, which are consistent with pure, 100
µM, 0.2 and 0.08 nM dye results. The blue wavelength illustrated the spectrum of cytoplasm which
contains rhodamine, and the red wavelength showed the spectrum of the cell nucleoplasm. The
bars in Fig 34c demonstrated the diversity of intensity data point of peak1 which is higher than
peak2, this variety consistent with peaks variations of the pure, 100 µM 0.2 and 0.08 nM
rhodamine data. The intensities here become much lower in compare with higher concentration
points. Therefore, 0.01 nM consider being be the minimum detectable concentration of rhodamine
6G by the spectral imaging system in comparing with 0.2 nM which is the minimum concentration
to detect by Q- TOF system. Furthermore, we conducted a linear regression analysis to check the
validity of our data point of Rhodamine 6G. Fig 35a represented the linearity result of the average
intensities of peak 1 vs log of different concentrations in M, the data showed a good linear
relationship result at R2= 0.85. Therefore, we can consider it as a stander peak for Rhodamine in
this research. While Fig 35b illustrated the linear relationship between the average intensities of
peak 2 and the log of concentrations in M, it showed less linearity in comparing with peak 1 at R2=
0.72. Fig 35c demonstrated the linearity of the ratio of average intensities for peak 1/peak 2, the
linear relationship between these data point is less in comparing with peak 1 and peak 2 at R2=
0.17.
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Figure 34. (a) Cells treated with 0.01 µM of Rhodamine 6G brightfield image by using brightfield
filter, spectral image by using SKY filter which clarified the result of uploaded Rhodamine library
and merged image of both brightfield and spectral images. (b) The graph showed Rhodamine 6G
fluorescence wavelength at ~ 580 nm, 670 nm in the cells, X= wavelengths and Y= signal
intensity. The blue wavelength described the area that has Rhodamine fluorescence which is the
cytoplasm, while red wavelength demonstrated the spectrum of the nucleoplasm. (c) The bars
interpret the data point intensity variation of peak1 which is higher than peak2, this diversity
consistent with peaks variations of the pure, 100 µM, 0.2 and 0.08 nM Rhodamine data. The
intensities here also become lower in comparing with higher concentrations of rhodamine.
Therefore, 0.01 nM consider being be the minimum detectable concentration of rhodamine by
spectral imaging.
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Figure 35. Linear regression analysis of Rhodamine 6G data by spectral imaging. X= log
of concentrations in M, Y= average of signal intensity. (a) The graph represented the average
intensities of peak 1 ( ~ 580 nM) vs the concentrations, and here we can consider peak 1
because of its show good linearity at R2= 0.85. (b) This graph demonstrated the peak 2
average intensities, it showed less linearity in comparing with peak 1 at R2= 0.72. (c)
illustrated the ratio of average intensities for peak 1/peak 2, which has less linearity in
comparing with peak 1 and peak 2 at R2= 0.17.
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3.3.2. Doxorubicin Spectral Imaging Result
Since spectral imaging system was able to identify the amount and location of Rhodamine 6G
within cell samples, we further tested another chemical with the same approach. To check pure
Doxorubicin fluorescence wavelength, spectral imaging was conducted by using SKY filter to
have the spectrum at ~ 592 nm which is consistent with the spectrophotometer fluorescence
spectrum. However, an additional wavelength peak at ~ 670 nm also appears with Doxorubicin
which we didn’t identify this peak yet (Fig 36b). For cell analysis, these wavelengths were
uploaded and saved as libraries files. As shown in Fig 36a brightfield filter was used to capture
brightfield image of pure Doxorubicin, used SKY filter to capture the spectral image, it represent
the analysis of uploaded wavelengths library and merged image that combined between brightfield
and spectral images. The graph in Fig 36b illustrated pure Doxorubicin fluorescence wavelength
at ~ 592 nm, 670 nm. The inside interprets the area that contains higher wavelength intensity based
on brighter chemical fluorescence in comparing with the peripheral area which contains less. The
background showed the wavelength intensity of the chemical background area, which should be
any spectrum but not doxorubicin spectrum. In addition, the bar graph Fig 36c showed the variety
of intensity data point result of peak1 which is higher than peak2. Next, we treated the cells with
different concentrations of Doxorubicin, starting with 150 nM since it was the maximum
detectable concentration limit by Q- TOF. Fig 37a displayed the negative control images which
are untreated cells, starting with brightfield image by brightfield filter, spectral image by SKY
filter and merged images. Fig 37b showed wavelength differences between cytoplasm and
nucleoplasm which reflect the background in comparing with the positive control (pure
Doxorubicin).
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Figure 36. (a) Brightfield image of pure Doxorubicin by using brightfield filter, spectral image
by using SKY filter which exemplified the analysis of uploaded library and merged image which
combines between brightfield and spectral images. (b) The graph demonstrated the fluorescence
wavelength of pure Doxorubicin at ~ 592 nm, 670 nm, X= wavelengths, and Y= signal intensity.
Inside showed the area that covers higher intensity and brighter chemical fluorescence in
comparing with the peripheral zone whereas background displayed Doxorubicin wavelength of
the background region. (c) The bar graph exhibited the variation of the intensity data point result
for peak1 which is higher than peak2.
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Figure 37. (a) Untreated cells which are considered to be the negative control in the study. The
brightfield image captured by using brightfield filter, spectral image by using SKY filter and
merged image which combined between brightfield and spectral images. (b) The graph illustrated
the fluorescence wavelengths of the negative control which reflect the background in comparing
with positive control. X= wavelengths and Y= signal intensity. (c) The bars indicated the data
point of the intensity variation for untreated cells.
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Cells treated with 150 nM of Doxorubicin are shown in Fig 38a as brightfield image which was
taken with brightfield filter, spectral image by SKY filter which is the result of the uploaded
libraries of pure Doxorubicin and merged of brightfield and spectral images. The spectral image
revealed Doxorubicin location in the cell which is specified in the nucleoplasm. Fig 38b exhibited
different fluorescence wavelengths of 150 nM treated cells at ~ 592, 670 nm, which are consistent
with the pure chemical results. However, there is an additional small peak at ~ 520 and we didn’t
yet identify this peak. The blue wavelength represents the nucleoplasm spectrum of Doxorubicin,
and red wavelength showed the background spectrum which is cell cytoplasm. The bar graph in
Fig 38c illustrated the variety of intensity data point results of peak1 which is higher than peak2,
this variety consistent with peaks variations of the pure Doxorubicin. Furthermore, we treated cells
with lower concentrations of Doxorubicin, 100 nM Fig 39, 10 nM Fig 40 and 1 nM fig 41. At all
of these figures, (a) represented the brightfield image that captured by brightfield filter, a spectral
image which is the results of uploaded library analysis done by using SKY filter and merged image
which is combine between spectral and brightfield images. (b) The graph showed different
wavelength intensities of 592 and 670 nm based on the location. The blue spectrum displayed the
area that has Doxorubicin in the sample, and the red spectrum exhibits the background region
which is cytoplasm. (c) The bars explained the intensity data point variation for peak 1 that is
higher than peak 2, the variation consistent with pure, 150 nM of doxorubicin. In general, within
cell samples, the intensities become lower at each concentration 150 – 1 nM in comparing with
pure Doxorubicin.
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Linear regression analysis performed to check the validity of our data point of Doxorubicin. Fig
42a showed the linearity result of the average intensities of peak1 vs log of different
concentrations, the data displayed an excellent linear relationship result at R2= 0.93. Therefore, we
can consider it as a standard peak for Doxorubicin in this study. While Fig 42b demonstrated the
linear relationship between the average intensities of peak 2 and the log of concentrations. It
displayed less linearity in comparison with peak 1 at R2= 0.76. In addition, Fig 43a illustrated the
linearity of the ratio of average intensities for peak 1/peak 2, the linear relationship between these
data point is less as compared with peak1 and peak2 at R2= 0.62. The graph in Fig 43b showed the
percentage of the abnormal cells (specifically abnormal nucleoplasm) of the samples, this done by
counting the abnormal nucleoplasm at each sample image, the percentage of the abnormality
increases with higher concentrations of Doxorubicin.

55

Brightfield

Spectral

Merged

150 nM

a.

100

c.

Nucleoplasm
Cytoplasm

80

Peak1
Peak1

60

Signal Intensity

Signal Intensity

b.

Peak2

40
20
0
400

500

600

700

800

80
60
40
20
0

Peak 1

Peak1

Wavelength (nm)

Peak 2

Peak2

Figure 38. (a) Brightfield image of the cells which are treated with 150 nM of Doxorubicin by
using brightfield filter, spectral image by using SKY filter which displayed the result of uploaded
doxorubicin library and merged image of brightfield and spectral images. (b) The graph represented
Doxorubicin fluorescence wavelength at ~ 592 nm, 670 nm inside the cells, X= wavelengths and
Y= signal intensity. The blue wavelength shows the region that contains Doxorubicin fluorescence
which is in the nucleoplasm, whereas red wavelength illustrated the spectrum of the background
area which is cell cytoplasm. (c) The bar graph explained the intensity data point variety for peak1
which is higher than peak2 and this variation in consistent with pure Doxorubicin data results. The
intensities here become lower in comparing with pure Doxorubicin since we prepared lower
concentration.
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Figure 39. (a) Cell samples that treated with 100 nM of Doxorubicin, brightfield image done by
using brightfield filter, spectral image by SKY filter which showed the result of uploaded
Doxorubicin library and merged image between of brightfield and spectral images. (b) The graph
illustrated Doxorubicin fluorescence wavelength at ~ 592 nm, 670 nm inside the cells, X=
wavelengths and Y= signal intensity. The blue wavelength displays the area that contains
Doxorubicin fluorescence which is in the nucleoplasm, while red wavelength showed the spectrum
of the background region which is cell cytoplasm. (c) The bar graph explained the intensity data
point variation for peak1 which is higher than peak2, and this variation in consistent with pure, 150
nM of Doxorubicin results. The intensities here become lower in comparing with pure, 150 nM
Doxorubicin.
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Figure 40. (a) Brightfield image is done by brightfield filter of cells that treated with 10 nM of
Doxorubicin, spectral image by SKY filter which displayed the uploaded Doxorubicin library result
and merged image of brightfield and spectral images. (b) The graph showed Doxorubicin
fluorescence wavelength at ~ 592 nm, 670 nm inside the cells, X= wavelengths and Y= signal
intensity. The blue wavelength illustrated the area that contains Doxorubicin fluorescence which is
in the nucleoplasm, while red wavelength showed the spectrum of the background area which is in
the cytoplasm. (c) The bar graph displayed the variation of intensity data point for peak1 that is
higher than peak2, this variation in consistent with pure, 150, 100 nM of Doxorubicin results. The
intensities here become lower in comparing with pure, 150, 100 nM Doxorubicin.
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Figure 41. (a) Cells that treated with 10 nM of Doxorubicin, brightfield image by brightfield filter,
spectral image by SKY filter which showed the result of uploaded Doxorubicin library and merged
image of brightfield and spectral images. (b) The graph illustrated Doxorubicin fluorescence
wavelength at ~ 592 nm, 670 nm inside the cells, X= wavelengths and Y= signal intensity. The blue
wavelength displayed the region that contains Doxorubicin fluorescence which is in the
nucleoplasm, while red wavelength explained the spectrum of the background area which is cell
cytoplasm. (c) The bar graph exhibited the intensity data point variety of peak1 that is higher than
peak2, this variety in consistent with pure, 150, 100, 10 nM of Doxorubicin results. The intensities
here also become lower in comparing with pure, 150, 100, 10 nM Doxorubicin.
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Figure 42. Linear regression analysis of Doxorubicin data by spectral imaging. X= log of
concentrations in M, Y= average of signal intensity. (a) The graph illustrated the average
intensities of peak 1 ( ~ 592 nM) vs the concentrations, here we can consider peak 1 because
of its show excellent linearity at R2= 0.9. While graph (b) explained peak 2 average intensities,
it showed less linearity in comparing with peak 1 at R2= 0.76.
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Figure 43. Linear regression analysis of Doxorubicin data by spectral imaging. X= log of
concentrations in M, Y= average of signal intensity. (a) The graph demonstrated the ratio of
average intensities for peak 1/peak 2, which has less linearity in comparing with peak 1 and peak
2 at R2= 0.62. (b) The graph displayed the percentage of the abnormal cells (specifically
abnormal nucleoplasm) of the samples, the percentage increase with higher concentrations of
Doxorubicin.

61

3.3.3. Au and Ag NPs Spectral Imaging Result
For the reason that NPs have no fluorescence, spectral imaging system was conducted by using
brightfield filter for pure Au and Ag NPs at ~ 536 nm and 420, respectively. These wavelengths
are in consistent with Spectrophotometer results, and the wavelengths were uploaded and saved as
libraries files for cell analysis. For Au NPs results, Fig 44a showed the brightfield image which
was performed by brightfield filter, the spectral image which represents the analysis of uploaded
wavelengths library of the brightfield image and merged image that combined between brightfield
and spectral images. The graph in Fig 44b demonstrated the pure Au NPs wavelength at ~ 536 nm.
The blue wavelength interpreted the area that contains higher wavelength intensity based on
brighter NPs analysis (bigger particle size) in comparison with a red wavelength which showed
the region that contains less (smaller particle size). The background displayed the wavelength
intensity of the NPs background area, which is exhibited by black color spectrum. In addition, the
bar graph in Fig 44c illustrated the intensity data point variation of Au NPs peak. Fig 45a showed
the untreated cells images which are negative control, starting with brightfield image by brightfield
filter, the spectral image which is the result for library analysis of brightfield image and merged
images between them. Fig 45b showed wavelengths differences between many areas in the cell
sample which reflect the background in comparing with the positive control (pure Au NPs).
Forwards, we treat the cells with 100 mg/mL of Au NPs for 18 hrs. Fig 46a explained the
brightfield image which was done by brightfield filter, a spectral image which is the result of the
uploaded libraries for the pure Au NPs of brightfield image and merged between brightfield and
spectral images. Brightfield image revealed Au NPs location in the cell which is in both
nucleoplasm and cytoplasm. Fig 46b exhibited different wavelengths of the treated cells with 100
mg/mL at ~ 536 nm, which are consistent with pure Au NPs results. The blue wavelength
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represented the region that has higher intensity based on brighter NPs analysis (bigger particle
size), whereas the red spectrum showed the area that contains less (smaller particle size).
Background displayed as a black color wavelength of the NPs background area. Fig 46c illustrated
the intensity data point variation of the peak, here we might have an intensity that higher than one
in the pure result, this is because we work with NPs which are not depending on the concentrations
anymore; instead, it depends on the particles size. The chart in Fig 47 summarized the Au NPs
results, the data for spectrum intensity of the pure Au NPs are higher than the negative control
(untreated cells) sample. However, in the cells which treated with 100 mg/mL of Au NPs, we have
in some points higher intensity in comparing with pure. This is because the analysis depend on the
NPs size. The most interesting step when we treated the cells with 100 mg/mL of Ag NPs, Fig 48a
illustrated the brightfield image which was performed by brightfield filter, the spectral image
which showed the analysis of uploaded wavelengths library of the brightfield image and merged
image of between brightfield and spectral images. The graph in Fig 48b displayed the pure Ag NPs
wavelengths at ~ 420 nm, 762 nm. The pink wavelength interpreted the area that contained the
core of Ag NPs, while the yellow wavelength showed the region that included shell of Ag NPs.
Both at the same wavelength but different spectrum shape. The background was showed as a black
spectrum of the area which contains no Ag NPs. In addition, the bar graph in Fig 48c illustrated
the intensity data point variation of peak1 which is higher than peak2. As well as Fig 49a showed
the negative control of untreated cells images, the brightfield image performed by brightfield filter,
spectral image is the result for library analysis of brightfield image and merged image between
brightfield and spectral images. Fig 49b displayed wavelengths intensity at ~ 455, 777 nm of
different areas in the cell sample which reflect the background in comparing with the positive
control (pure Ag NPs). Fig 49c the bar graph represented the different background intensity
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between peak1 and peak2 which is the highest. Moreover, we treated the cells with 100 mg/mL
of Ag NPs. Fig 50a illustrated the brightfield image which was conducted by brightfield filter, the
spectral image which is the uploaded libraries result for the pure Ag NPs of brightfield image and
merged image of brightfield and spectral images. Brightfield image explained Ag NPs location in
the cell sample which is in the nucleoplasm and cytoplasm. Fig 50b displayed wavelengths
differences (at ~ 420, 762 nm) between the core spectrum in pink color and the shell in yellow
within the cell sample, the black spectrum reflected the background area of the NPs. Fig 50c the
bar graph displayed the intensity wavelengths differences between peak1 which is higher than
peak2, these data also consistent with pure Ag NPs results. The chart in Fig 51 summarized the
Ag NPs results, (a) illustrated the average differences between peak1 of pure Ag NPs (at ~420
nm), negative control (~ 455 nm) and cells that treated with Ag NPs (at 420 nm). Peak2 of pure
Ag NPs (at ~762 nm), negative control (~ 777 nm) and cells were treated with Ag NPs (~ 762 nm).
While (b) explained the results of the intensity average of peak1/peak1 of pure Ag NPs which are
higher than Ag NPs within the cells and negative control.
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Figure 44. (a) Brightfield image of pure Au NPs done by using brightfield filter, the spectral image
which is the result for the uploaded library analysis of brightfield image and merged image which
combine between brightfield and spectral images. (b) The graph demonstrated the wavelengths of
pure Au NPs at ~ 536 nm, X= wavelengths, and Y= signal intensity. The blue wavelength displayed
the area that contains higher wavelength intensity based on brighter NPs analysis (bigger particle
size), while red wavelength showed the region that includes less (smaller particle size). Background
exhibited as a black color wavelength of the NPs background area. (c) The bar graph exhibited the
intensity data point variation result for Au NPs peak.
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Figure 45. (a) Negative control of untreated cells. The brightfield image captured by using
brightfield filter, spectral image is the result of library analysis of brightfield image and merged
image which combined between brightfield and spectral images. (b) The graph demonstrated the
wavelengths of the negative control which reflect the background in comparing with the positive
control (pure Au NPs). X= wavelengths and Y= signal intensity. (c) The bars indicated the intensity
variation of the data point for untreated cells.
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Figure 46. (a) Cell samples which are treated with 100 mg/mL of pure Au NPs, brightfield image
done by using brightfield filter, the spectral image which showed the result of uploaded Au NPs
library of brightfield image and merged image between the brightfield and spectral images. (b) The
graph demonstrated Au NPs wavelength at ~ 536 nm inside the cells, X= wavelengths, and Y=
signal intensity. The blue wavelength displayed the area that contains high intensity wavelength
(bigger particle size), while the red wavelength showed less intensity (smaller particle size). (c) The
bar graph explained the intensity data point variation for Au NPs peak, we may have higher intensity
data because it depend on the particle size.
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Figure 47. The chart summarized the Au NPs data results analysis. As is shown, the
data for the wavelength intensity of the pure Au NPs is higher than the negative control.
However, in the cells which treated with 100 mg/mL of Au NPs, we have in some
points higher intensity in comparing with pure. This is because we work with NPs
which are dependent on the particle size.
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Figure 48. (a) Brightfield image of pure Ag NPs done by brightfield filter, the spectral image which
is the analysis result for the uploaded library of brightfield image and merged image of brightfield
and spectral images. (b) The graph illustrated the wavelengths of pure Au NPs at ~ 420, 762 nm, X=
wavelengths, and Y= signal intensity. The pink wavelength displayed the intensity of the core area of
Ag NPs, while the yellow wavelength showed the shell region. Background exhibits as a black color
spectrum of the NPs background area. (c) The bar graph exhibited the intensity data point variation
result for peak1 which is higher than peak2.
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Figure 49. (a) Negative control of untreated cells, brightfield image by brightfield filter, the spectral
image which is the result for the uploaded library analysis of brightfield image and merged image
of brightfield and spectral images. (b) The graph illustrated the wavelengths of the negative control
at ~ 455, 777 nm which we consider it as a background, X= wavelengths, and Y= signal intensity.
(c) The bar graph exhibited the intensity data point variation for peak1 which is lower than peak2.

70

Brightfield

Spectral

Merged

Ag NPs

a.

c.

b.

15

10

Signal Intensity

Signal Intensity

12

Ag NP
core
Ag NP

8

peripheral
Backgrou
nd

6
4
2

10
5
0

0
400

500

600

700

800

peak 1

peak 2

Peak1 Peak2

Wavelength
Figure 50. (a)(nm)
Cells that treated with 100 mg/mL of Ag NPs, the brightfield image done by
brightfield filter, the spectral image which is the analysis result for the uploaded library of brightfield
image and merged image of brightfield and spectral images. (b) The graph illustrated the wavelengths
of pure Au NPs at ~ 420, 762 nm, X= wavelengths, and Y= signal intensity. The pink wavelength
demonstrated the intensity of the core area of Ag NPs, whereas yellow wavelength displayed the
shell region. Background exhibited as a black color spectrum of the NPs background area. (c) The
bar graph show the intensity data point variation for peak1 which is higher than peak2. This variation
result is consistent with pure Ag NPs results.

71

Signal Intensity

a.

Signal Intensity

b.

Peak1

Peak2

50

20

40

15

30

10

20

5

10
0

Pure

Neg

Ag

0

Pure

Neg

Ag

15 Peak1/Peak2

Pure Ag NPs

10

Negative Control

5

Ag NPs
0

Pure

Neg

Ag

Figure 51. Summarized the Ag NPs analysis results, (a) explained the average
differences between peak1 of pure Ag NPs (at ~420 nm), negative control (~ 455 nm)
and cells that treated with 100 mg/mL of Ag NPs (at 420 nm). Peak2 of pure Ag NPs
(at ~762 nm), negative control (~ 777 nm) and treated cells (~ 762 nm). While chart
(b) demonstrated the results of the peak1/peak1 average of pure Ag NPs, which are
higher than Ag NPs within the cells and negative control.
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Chapter 4
CONCLUSION

The spectral imaging is a powerful technique which can capture the image of the sample and
displays a spectrum at each pixel of our target. This feature provides the researchers with full and
details information about the samples in a way that can help to enhance the understanding of many
topics and questions. For instance, it allows the identification of the exact location and quantity of
our sample in the cells. In this study, spectral imaging was conducted to test many chemicals
including rhodamine 6g, doxorubicin, Au NPs and Ag NPs. Spectral imaging was able to identify
each sample by the spectrum of the molecule; this done by uploading each spectrum of the pure
chemicals as a library and use it for cells analysis. In addition, spectral imaging was capable to
identify each molecule within cells by the library of the molecule wavelength. However, we
observed extra peaks which are not consistent with the spectrophotometer and need to be
identified.
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